Association of serum leptin and adiponectin concentrations with echocardiographic parameters and pathophysiological states in patients with cardiovascular disease receiving cardiovascular surgery


Autoři: Tatsuya Sawaguchi aff001;  Toshiaki Nakajima aff001;  Akiko Haruyama aff001;  Takaaki Hasegawa aff001;  Ikuko Shibasaki aff002;  Takafumi Nakajima aff001;  Hiroyuki Kaneda aff001;  Takuo Arikawa aff001;  Syotaro Obi aff001;  Masashi Sakuma aff001;  Hironaga Ogawa aff002;  Yuusuke Takei aff002;  Shigeru Toyoda aff001;  Fumitaka Nakamura aff003;  Shichiro Abe aff001;  Hirotsugu Fukuda aff002;  Teruo Inoue aff001
Působiště autorů: Department of Cardiovascular Medicine, Dokkyo Medical University, Tochigi, Japan aff001;  Department of Cardiovascular Surgery, Dokkyo Medical University, Tochigi, Japan aff002;  Third Department of Internal Medicine, Teikyo University, Chiba Medical Center, Japan aff003
Vyšlo v časopise: PLoS ONE 14(11)
Kategorie: Research Article
doi: 10.1371/journal.pone.0225008

Souhrn

Leptin and adiponectin are important regulators of energy metabolism and body composition. Leptin exerts cardiodepressive effects, whereas adiponectin has cardioprotective effects, but several conflicting findings have been reported. The aim of the present study was to assess the relationship between serum leptin and adiponectin levels and echocardiographic parameters and pathophysiological states in patients with cardiovascular disease (CVD) receiving cardiovascular surgery. A total of 128 patients (79 males, average age 69.6 years) that had surgery for CVD including coronary artery bypass graft (CABG) and valve replacement were recruited in this study. Preoperative serum adiponectin and leptin concentrations were measured by enzyme-linked immunosorbent assay and compared with preoperative echocardiographic findings. Body fat volume and skeletal muscle volume index (SMI) were estimated using bioelectrical impedance analysis. We also measured grip strength and gait speed. Sarcopenia was diagnosed based on the recommendations of the Asian Working Group on Sarcopenia. Positive correlations were found between adiponectin and brain natriuretic peptide (BNP), age, left atrial diameter (LAD), E/e’ (early-diastolic left ventricular inflow velocity / early-diastolic mitral annular velocity), and left atrial volume index (LAVI). Negative correlations were observed between adiponectin and body mass index (BMI), estimated glomerular filtration rate (eGFR), triglyceride, hemoglobin, and albumin. Serum leptin was positively correlated with BMI, total cholesterol, triglyceride, albumin, body fat volume, and LV ejection fraction (LVEF), whereas it was negatively correlated with BNP and echocardiographic parameters (LAD, LV mass index (LVMI), and LAVI). Multiple regression analysis showed associations between log (leptin) and log (adiponectin) and echocardiographic parameters after adjusting for age, sex, and BMI. Serum adiponectin was negatively correlated with leptin, but positively correlated with tumor necrosis factor α (TNFα), an inflammatory cytokine. In males, serum leptin level had a positive correlation with skeletal muscle volume and SMI. However, adiponectin had a negative correlation with anterior mid-thigh muscle thickness, skeletal muscle volume and SMI. And, it was an independent predictive factor in males for sarcopenia even after adjusted by age. These results suggest that leptin and adiponectin may play a role in cardiac remodeling in CVD patients receiving cardiovascular surgery. And, adiponectin appears to be a marker of impaired metabolic signaling that is linked to heart failure progression including inflammation, poor nutrition, and muscle wasting in CVD patients receiving cardiovascular surgery.

Klíčová slova:

Adiponectin – Adipose tissue – Cardiovascular diseases – Cardiovascular procedures – Heart failure – leptin – Sarcopenia – Skeletal muscles


Zdroje

1. Hopkins TA, Ouchi N, Shibata R, Walsh K. Adiponectin actions in the cardiovascular system.Cardiovasc Res. 2007 Apr 1;74(1):11–18. Epub 2006 Oct 20. doi: 10.1016/j.cardiores.2006.10.009 17140553

2. Marinou K, Tousoulis D, Antonopoulos AS, Stefanadi E, Stefanadis C. Obesity and cardiovascular disease: from pathophysiology to risk stratification. Int J Cardiol. 2010 Jan 7;138(1):3–8. doi: 10.1016/j.ijcard.2009.03.135 19398137

3. Stofkova A. Leptin and adiponectin: from energy and metabolic dysbalance to inflammation and autoimmunity. Endocr Regul. 2009 Oct;43(4):157–168. Review 19908934

4. Friedman JM, Halaas JL. Leptin and the regulation of body weight in mammals. Nature. 1998 Oct 22;395(6704):763–770. Review. doi: 10.1038/27376 9796811

5. Lee JH, Reed DR, Price RA. Leptin resistance is associated with extreme obesity and aggregates in families. Int J Obes Relat Metab Disord. 2001 Oct;25(10):1471–1473. doi: 10.1038/sj.ijo.0801736 11673768

6. Maresca F, Di Palma V, Bevilacqua M, Uccello G, Taglialatela V, Giaquinto A, et al. Esposito G, Trimarco B, Cirillo P. Adipokines, vascular wall, and cardiovascular disease: a focused overview of the role of adipokines in the pathophysiology of cardiovascular disease. Angiology. 2015 Jan;66(1):8–24. doi: 10.1177/0003319713520463 24535638

7. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005 May;26(3):439–451. Review. doi: 10.1210/er.2005-0005 15897298

8. Tao L, Gao E, Jiao X, Yuan Y, Li S, Christopher TA, et al. Adiponectin cardioprotection after myocardial ischemia/reperfusion involves the reduction of oxidative/nitrative stress Circulation. 2007 Mar 20;115(11):1408–1416. Epub 2007 Mar 5. doi: 10.1161/CIRCULATIONAHA.106.666941 17339545

9. Hui X, Lam KS, Vanhoutte PM, Xu A. Adiponectin and cardiovascular health: an update. Br J Pharmacol. 2012 Feb;165(3):574–590. doi: 10.1111/j.1476-5381.2011.01395.x 21457225

10. Hong SJ, Park CG, Seo HS, Oh DJ, Ro YM. Associations among plasma adiponectin, hypertension, left ventricular diastolic function and left ventricular mass index. Blood Press. 2004;13(4):236–242. 15581338

11. Keren G, Roth A. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006 Oct;92(10):1420–1424. doi: 10.1136/hrt.2005.083345 16621874

12. Mitsuhashi H, Yatsuya H, Tamakoshi K, Matsushita K, Otsuka R, Wada K, et al. Adiponectin level and left ventricular hypertrophy in Japanese men. Hypertension. 2007 Jun;49(6):1448–1454. doi: 10.1161/HYPERTENSIONAHA.106.079509 17420337

13. Fontes-Carvalho R, Pimenta J, Bettencourt P, Leite-Moreira A, Azevedo A. Association between plasma leptin and adiponectin levels and diastolic function in the general population. Expert Opin Ther Targets. 2015;19(10):1283–1291. doi: 10.1517/14728222.2015.1019468 25787844

14. Wilson SR, Sabatine MS, Wiviott SD, Ray KK, De Lemos JA, Zhou S, et al. Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the Pravastatin Or atorVastatin Evaluation and Infection Trial-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22). Am Heart J. 2011 Jun;161(6):1147–1155. doi: 10.1016/j.ahj.2011.02.014 21641362

15. Lindberg S, Pedersen SH, Møgelvang R, Bjerre M, Frystyk J, Flyvbjerg A, et al. Usefulness of adiponectin as a predictor of all cause mortality in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention. Am J Cardiol. 2012 Feb 15;109(4):492–496. doi: 10.1016/j.amjcard.2011.09.041 22105783

16. George J, Patal S, Wexler D, Sharabi Y, Peleg E, Kamari Y, et al. Circulating adiponectin concentrations in patients with congestive heart failure. Heart. 2006 Oct;92(10):1420–1424. Epub 2006 Apr doi: 10.1136/hrt.2005.083345 16621874

17. Haugen E, Furukawa Y, Isic A, Fu M. Increased adiponectin level in parallel with increased NT-pro BNP in patients with severe heart failure in the elderly: A hospital cohort study. Int J Cardiol. 2008 Apr 10;125(2):216–219. doi: 10.1016/j.ijcard.2007.12.002 18234365

18. Bobbert P, Scheibenbogen C, Jenke A, Kania G, Wilk S, Krohn S, et al. Adiponectin expression in patients with inflammatory cardiomyopathy indicates favorable outcome and inflammation control. Eur Heart J. 2011 May;32(9):1134–1147. doi: 10.1093/eurheartj/ehq498 21278397

19. Mikkelsen MM, Hansen TK, Gjedsted J, Andersen NH, Christensen TD, Hjortdal VE, et al. Insulin resistance, adiponectin and adverse outcomes following elective cardiac surgery: a prospective follow-up study. J Cardiothorac Surg. 2010 Dec 14;5:129. doi: 10.1186/1749-8090-5-129 21156037

20. McEntegart MB, Awede B, Petrie MC, Sattar N, Dunn FG, MacFarlane NG, et al. Increase in serum adiponectin concentration in patients with heart failure and cachexia: relationship with leptin, other cytokines, and B-type natriuretic peptide. Eur Heart J. 2007 Apr;28(7):829–835. doi: 10.1093/eurheartj/ehm033 17403719

21. von Haehling S, Lainscak M, Springer J, Anker SD. Cardiac cachexia: a systematic overview. Pharmacol Ther. 2009 Mar;121(3):227–252. doi: 10.1016/j.pharmthera.2008.09.009 19061914

22. Abel ED, Litwin SE, Sweeney G. Cardiac remodeling in obesity. Physiol Rev. 2008 Apr;88(2):389–419. doi: 10.1152/physrev.00017.2007 18391168

23. Lauer MS, Anderson KM, Kannel WB, Levy D. The impact of obesity on left ventricular mass and geometry. The Framingham Heart Study. JAMA. 1991 Jul 10;266(2):231–236. 1829117

24. Fischer M, Baessler A, Hense HW, Hengstenberg C, Muscholl M, Holmer S, et al. Prevalence of left ventricular diastolic dysfunction in the community. Results from a Doppler echocardiographic-based survey of a population sample. Eur Heart J. 2003 Feb;24(4):320–328. doi: 10.1016/s0195-668x(02)00428-1 12581679

25. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, et al. Obesity and the risk of heart failure. N Engl J Med. 2002 Aug 1;347(5):305–313. doi: 10.1056/NEJMoa020245 12151467

26. Rajapurohitam V, Gan XT, Kirshenbaum LA, Karmazyn M. The obesity-associated peptide leptin induces hypertrophy in neonatal rat ventricular myocytes. Circ Res. 2003 Aug 22;93(4):277–279. doi: 10.1161/01.RES.0000089255.37804.72 12893740

27. Lieb W, Sullivan LM, Aragam J, Harris TB, Roubenoff R, Benjamin EJ, et al. Relation of serum leptin with cardiac mass and left atrial dimension in individuals >70 years of age. Am J Cardiol. 2009 Aug 15;104(4):602–605. doi: 10.1016/j.amjcard.2009.04.026 19660619

28. Martin SS, Blaha MJ, Muse ED, Qasim AN, Reilly MP, Blumenthal RS, et al. Leptin and incident cardiovascular disease: the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis. 2015 Mar;239(1):67–72. doi: 10.1016/j.atherosclerosis.2014.12.033 25574859

29. Sharma S, Colangelo LA, Allison MA, Lima JA, Ambale-Venkatesh B, Kishi S, et al. Association of serum leptin with future left ventricular structure and function: The Multi-Ethnic Study of Atherosclerosis (MESA). Int J Cardiol. 2015 Aug 15;193:64–68. doi: 10.1016/j.ijcard.2015.05.068 26005181

30. McGaffin KR, Sun CK, Rager JJ, Romano LC, Zou B, Mathier MA, et al. Leptin signalling reduces the severity of cardiac dysfunction and remodelling after chronic ischaemic injury. Cardiovasc Res. 2008 Jan;77(1):54–63. Epub 2007 Sep 20. doi: 10.1093/cvr/cvm023 18006469

31. Barouch LA, Berkowitz DE, Harrison RW, O'Donnell CP, Hare JM. Disruption of leptin signaling contributes to cardiac hypertrophy independently of body weight in mice. Circulation. 2003 Aug 12;108(6):754–759. Epub 2003 Jul doi: 10.1161/01.CIR.0000083716.82622.FD 12885755

32. Kaneda H, Nakajima T, Haruyama A, Shibasaki I, Hasegawa T, Sawaguchi T, et al. Association of serum concentrations of irisin and the adipokines adiponectin and leptin with epicardial fat in cardiovascular surgery patients. PLoS One. 2018 Aug 2;13(8):e0201499. doi: 10.1371/journal.pone.0201499 30071056

33. Sawaguchi T, Nakajima T, Hasegawa T, Shibasaki I, Kaneda H, Obi S, et al. Serum adiponectin and TNFα concentrations are closely associated with epicardial adipose tissue fatty acid profiles in patients undergoing cardiovascular surgery. Int J Cardiol Heart Vasc. 2017 Nov 28;18:86–95. doi: 10.1016/j.ijcha.2017.11.004 29750183

34. Yasuda T, Nakajima T, Sawaguchi T, Nozawa N, Arakawa T, Takahashi R, et al. Short Physical Performance Battery for cardiovascular disease inpatients: implications for critical factors and sarcopenia. Sci Rep. 2017 Dec 12;7(1):17425. doi: 10.1038/s41598-017-17814-z 29234165

35. Chen LK, Liu LK, Woo J, Assantachai P, Auyeung TW, Bahyah KS, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014 Feb;15(2):95–101. doi: 10.1016/j.jamda.2013.11.025 24461239

36. Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med. 1996 Feb 1;334(5):292–295. doi: 10.1056/NEJM199602013340503 8532024

37. Allison MA, Bluemke DA, McClelland R, Cushman M, Criqui MH, Polak JF, et al. Relation of leptin to left ventricular hypertrophy (from the Multi-Ethnic Study of Atherosclerosis). Am J Cardiol. 2013 Sep 1;112(5):726–730. doi: 10.1016/j.amjcard.2013.04.053 23711806

38. Meier U, Gressner AM. Endocrine regulation of energy metabolism: review of pathobiochemical and clinical chemical aspects of leptin, ghrelin, adiponectin, and resistin. Clin Chem. 2004 Sep;50(9):1511–1525. Epub 2004 Jul 20. Review. doi: 10.1373/clinchem.2004.032482 15265818

39. Wojciechowska C, Jacheć W, Romuk E, Nowalany-Kozielska E, Tomasik A, Siemińska L. The effect of BMI, serum leptin, and adiponectin levels on prognosis in patients with non-ischaemic dilated cardiomyopathy. Endokrynol Pol. 2017;68(1):26–34. doi: 10.5603/EP.2017.0005 28255978

40. Tsukamoto O, Fujita M, Kato M, Yamazaki S, Asano Y, Ogai A, et al. Natriuretic peptides enhance the production of adiponectin in human adipocytes and in patients with chronic heart failure. J Am Coll Cardiol. 2009 Jun 2;53(22):2070–2077. doi: 10.1016/j.jacc.2009.02.038 19477358

41. Antonopoulos AS, Margaritis M, Coutinho P, Digby J, Patel R, Psarros C, et al. Reciprocal effects of systemic inflammation and brain natriuretic peptide on adiponectin biosynthesis in adipose tissue of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol. 2014 Sep;34(9):2151–2159. doi: 10.1161/ATVBAHA.114.303828 25060790

42. Gustafsson S, Lind L, Zethelius B, Venge P, Flyvbjerg A, Söderberg S, et al. Adiponectin and cardiac geometry and function in elderly: results from two community-based cohort studies. Eur J Endocrinol. 2010 Mar;162(3):543–550. doi: 10.1530/EJE-09-1006 20008076

43. Won H, Kang SM, Shin MJ, Oh J, Hong N, Park S, et al. Plasma adiponectin concentration and its association with metabolic syndrome in patients with heart failure. Yonsei Med J. 2012 Jan;53(1):91–98. doi: 10.3349/ymj.2012.53.1.91 22187237

44. Baltrūnienė V, Bironaitė D, Kažukauskienė I, Bogomolovas J, Vitkus D, Ručinskas K, et al. The Role of Serum Adiponectin for Outcome Prediction in Patients with Dilated Cardiomyopathy and Advanced Heart Failure. Biomed Res Int. 2017;2017:3818292. doi: 10.1155/2017/3818292 Epub 2017 Nov 26. https://doi.org/10.1155/2017/3818292 29318144

45. Unno K, Shibata R, Izawa H, Hirashiki A, Murase Y, Yamada T, et al. Adiponectin acts as a positive indicator of left ventricular diastolic dysfunction in patients with hypertrophic cardiomyopathy. Heart. 2010 Mar;96(5):357–361. doi: 10.1136/hrt.2009.172320 19648128

46. Loncar G, Bozic B, von Haehling S, Düngen HD, Prodanovic N, Lainscak M, et al. Association of adiponectin with peripheral muscle status in elderly patients with heart failure. Eur J Intern Med. 2013 Dec;24(8):818–823. doi: 10.1016/j.ejim.2013.09.011 24095654

47. Huang C, Niu K, Momma H, Kobayashi Y, Guan L, Nagatomi R. Inverse association between circulating adiponectin levels and skeletal muscle strength in Japanese men and women. Nutr Metab Cardiovasc Dis. 2014 Jan;24(1):42–49. doi: 10.1016/j.numecd.2013.03.006 23786825

48. Karvonen-Gutierrez CA, Zheng H, Mancuso P, Harlow SD. Higher Leptin and Adiponectin Concentrations Predict Poorer Performance-based Physical Functioning in Midlife Women: the Michigan Study of Women's Health Across the Nation. J Gerontol A Biol Sci Med Sci. 2016 Apr;71(4):508–514. doi: 10.1093/gerona/glv123 26302979

49. Pisto P, Santaniemi M, Turpeinen JP, Ukkola O, Kesäniemi YA. Adiponectin concentration in plasma is associated with muscle fiber size in healthy middle-aged men. Scand J Clin Lab Invest. 2012 Sep;72(5):395–402. doi: 10.3109/00365513.2012.687759 22900744

50. Kung T, Szabó T, Springer J, Doehner W, Anker SD, von Haehling S. Cachexia in heart disease: highlights from the ESC 2010. J Cachexia Sarcopenia Muscle. 2011 Mar;2(1):63–69. doi: 10.1007/s13539-011-0020-z 21475672

51. Harada H, Kai H, Shibata R, Niiyama H, Nishiyama Y, Murohara T, et al. New diagnostic index for sarcopenia in patients with cardiovascular diseases. PLoS One. 2017 May 18;12(5):e0178123. eCollection 2017. doi: 10.1371/journal.pone.0178123 28542531

52. Araujo JP, Lourenco P, Rocha-Goncalves F, Ferrera A, Bettencourt P. Adiponectin is increased in cardiac cachexia irrespectively of body mass index. Eur J Fail. 2019; 11: 567–572. doi: 10.1093/eurjhf/hfp046 19359328

53. Bouillanne O, Golmard JL, Coussieu C, Noël M, Durand D, Piette F, et al. Leptin a new biological marker for evaluating malnutrition in elderly patients. Eur J Clin Nutr. 2007 May;61(5):647–654. doi: 10.1038/sj.ejcn.1602572 17151588

54. Amirkalali B, Sharifi F, Fakhrzadeh H, Mirarefein M, Ghaderpanahi M, Badamchizadeh Z, et al. Low serum leptin serves as a biomarker of malnutrition in elderly patients. Nutr Res. 2010 May;30(5):314–319. doi: 10.1016/j.nutres.2010.05.002 20579523

55. Yamaji M, Tsutamoto T, Tanaka T, Kawahara C, Nishiyama K, Yamamoto T, et al. Effect of carvedilol on plasma adiponectin concentration in patients with chronic heart failure. Circ J. 2009 Jun;73(6):1067–1073. doi: 10.1253/circj.cj-08-1026 19367012


Článek vyšel v časopise

PLOS One


2019 Číslo 11